Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial

Compugen (NASDAQ:CGEN) said its drug COM701 in dual and triple combination with Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) ± BMS-986207 (anti-TIGIT) showed preliminary durable anti-tumor activity and immune activation in patients with platinum resistant ovarian cancer in a trial.